Lack of Nigral Pathology in Transgenic Mice Expressing Human α-Synuclein Driven by the Tyrosine Hydroxylase Promoter

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240

AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease

Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836

α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868

A Drosophila model of Parkinson's disease

Feany, M. Β., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,156

Dopaminergic Loss and Inclusion Body Formation in α-Synuclein Mice: Implications for Neurodegenerative Disorders

Masliah, E., Rockenstein, E. M., Veinbergs, I., Mallory, M. E., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,779

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046

Pathoanatomy of Parkinson’s disease

Braak, H., & Braak, E. (2000) · Journal of Neurology · doi:10.1007/pl00007758 · Cited by 693

Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain

Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van der Putten, H., Probst, A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06365.2000 · Cited by 642

Neuropathology in Mice Expressing Human α-Synuclein

van der Putten, H., Wiederhold, K., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P. J. M., Rüegg, M. A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06021.2000 · Cited by 563

Neuropathology in mice expressing human alpha-synuclein

van der Putten, H., Wiederhold, K., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P. J. M., Rüegg, M. A., et al. (2000) · PubMed Central · doi:10.5451/unibas-ep2767 · Cited by 505

Parkinson's Disease

Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469

Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein

Lotharius, J., & Brundin, P. (2002) · Nature reviews. Neuroscience · doi:10.1038/nrn983 · Cited by 1,319

Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein

Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266

Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis

Nemani, V. M., Lü, W., Berge‐Seidl, V., Nakamura, K., Onoa, B., Lee, M. K., Chaudhry, F. A., Nicoll, R. A., & Edwards, R. H. (2010) · Neuron · doi:10.1016/j.neuron.2009.12.023 · Cited by 1,089

The scientific and clinical basis for the treatment of Parkinson disease (2009)

Olanow, C. W., Stern, M. B., & Sethi, K. D. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 947

The function of α-synuclein

Bendor, J. T., Logan, T. P., & Edwards, R. H. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.004 · Cited by 825

Genetic Animal Models of Parkinson's Disease

Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.034 · Cited by 866

Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice

Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824

Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System

Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02780.2002 · Cited by 649

Parkinson's Disease α-Synuclein Transgenic Mice Develop Neuronal Mitochondrial Degeneration and Cell Death

Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., & Lee, M. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4308-05.2006 · Cited by 684

The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice

Manning-Bog, A., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L., & Monte, D. A. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100560200 · Cited by 725

A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis

Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03090.2002 · Cited by 598

Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death

Stefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D., & Greene, L. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09549.2001 · Cited by 584

Parkin Protects against the Toxicity Associated with Mutant α-Synuclein

Petrucelli, L., O’Farrell, C., Lockhart, P. J., Baptista, M. J., Kehoe, K. J., Vink, L., Choi, P., Wolozin, B. L., Farrer, M. J., Hardy, J., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)01125-x · Cited by 561

Targeting programmed cell death in neurodegenerative diseases

Vila, M., & Przedborski, S. (2003) · Nature reviews. Neuroscience · doi:10.1038/nrn1100 · Cited by 566

Parkinson’s disease: animal models and dopaminergic cell vulnerability

Blesa, J., & Przedborski, S. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00155 · Cited by 515

Synuclein activates microglia in a model of Parkinson's disease

Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474

Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form

Lee, H.-J., Choi, C., & Lee, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107045200 · Cited by 462

Alzheimer disease models and human neuropathology: similarities and differences

Duyckaerts, C., Potier, M.-C., & Delatour, B. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0312-8 · Cited by 375

Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior

Mattson, M. P., Chan, S. L., & Duan, W. (2002) · Physiological Reviews · doi:10.1152/physrev.00004.2002 · Cited by 440

Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration

Gao, H., Kotzbauer, P. T., Uryu, K., Leight, S., Trojanowski, J. Q., & Lee, V. M. ‐. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0143-07.2008 · Cited by 453

α-Synuclein and neuronal cell death

Cookson, M. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-9 · Cited by 440

Historical Perspective: Models of Parkinson’s Disease

Chia, S. J., Tan, E., & Chao, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072464 · Cited by 438

Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease

Kirik, D., Annett, L. E., Bürger, C., Muzyczka, N., Mandel, R. J., & Björklund, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536383100 · Cited by 416

The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?

Monte, D. A. D. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00501-5 · Cited by 358

Misfolded proteinase K–resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies

Neumann, M., Kahle, P. J., Giasson, B. I., Ozmen, L., Borroni, E., Spooren, W. P. J. M., Müller, V., Odoy, S., Fujiwara, H., Hasegawa, M., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15777 · Cited by 363

The role of α-synuclein in Parkinson's disease: insights from animal models

Lad, E. M., Dass, B., Collier, T. J., Kordower, J. H., & Steece‐Collier, K. (2003) · Nature reviews. Neuroscience · doi:10.1038/nrn1199 · Cited by 357

Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line

Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H. K., & Brundin, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205518200 · Cited by 368

The Relevance of Iron in the Pathogenesis of Parkinson's Disease

Götz, M. E., Double, K. L., Gerlach, M., Youdim, M. B. H., & RIEDERERE, P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.017 · Cited by 343

Role of post-translational modifications in modulating the structure, function and toxicity of α-synuclein

Oueslati, A., Fournier, M., & Lashuel, H. A. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)83007-9 · Cited by 354

Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders

Tofaris, G. K., Garcia-Reitboeck, P., Humby, T., Lambourne, S. L., O’Connell, M. T., Ghetti, B. F., Gossage, H., Emson, P. C., Wilkinson, L. S., Goedert, M., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4965-05.2006 · Cited by 335

Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps

Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · APOPTOSIS · doi:10.1007/s10495-008-0309-3 · Cited by 300

Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice

Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285

Overexpression of α‐synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α‐synuclein and activation of caspase‐9: resemblance to pathogenetic changes in Parkinson's disease

YAMADA, M., Iwatsubo, T., Mizuno, Y., & Mochizuki, H. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02728.x · Cited by 278

Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease

Lotharius, J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2395 · Cited by 273

Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease

Dev, K. K. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00140-0 · Cited by 267

Molecular pathogenesis of Parkinson's disease

Gandhi, S., & Wood, N. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi308 · Cited by 251

The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease

Benskey, M. J., Perez, R. G., & Manfredsson, F. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13570 · Cited by 257

Molecular mechanisms of α-synuclein neurodegeneration

Waxman, E. A., & Giasson, B. I. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.09.013 · Cited by 247

α-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration

Manning-Bog, A., McCormack, A. L., Purisai, M. G., Bolin, L. M., & Monte, D. A. D. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03095.2003 · Cited by 242

Rare genetic mutations shed light on the pathogenesis of Parkinson disease

Dawson, T. M., & Dawson, V. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17575 · Cited by 242

Animal models of α-synucleinopathy for Parkinson disease drug development

Koprich, J. B., Kalia, L. V., & Brotchie, J. M. (2017) · Nature reviews. Neuroscience · doi:10.1038/nrn.2017.75 · Cited by 241

Evaluation of Models of Parkinson's Disease

Jagmag, S. A., Tripathi, N., Shukla, S. D., Maiti, S., & Khurana, S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00503 · Cited by 244

Dopaminergic Cell Loss Induced by Human A30P α -Synuclein Gene Transfer to the Rat Substantia Nigra

Klein, R. L., King, M. A., Hamby, M. E., & Meyer, E. M. (2002) · Human Gene Therapy · doi:10.1089/10430340252837206 · Cited by 212

Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease

McNaught, K. S. P., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10512 · Cited by 203

α-Synuclein: Normal Function and Role in Neurodegenerative Diseases

Norris, E. H., Giasson, B. I., & Lee, V. M. ‐. (2004) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(04)60002-0 · Cited by 208

Familial Parkinson Mutant α-Synuclein Causes Dopamine Neuron Dysfunction in Transgenic Caenorhabditis elegans

Kuwahara, T., Koyama, A., Gengyo‐Ando, K., Masuda, M., Kowa, H., Tsunoda, M., Mitani, S., & Iwatsubo, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504860200 · Cited by 205

Reverse engineering Lewy bodies: how far have we come and how far can we go?

Fares, M. B., Jagannath, S., & Lashuel, H. A. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-00416-6 · Cited by 205

Alpha-synuclein and transgenic mouse models

Fernagut, P., & Chesselet, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.001 · Cited by 210

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration

Duffy, M. F., Collier, T. J., Patterson, J. R., Kemp, C. J., Luk, K. C., Tansey, M. G., Paumier, K. L., Kanaan, N. M., Fischer, D. L., Polinski, N. K., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1171-z · Cited by 197

Neurotoxic in vivo models of Parkinson’s disease

Cannon, J. R., & Greenamyre, J. T. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84002-6 · Cited by 198

MPTP: a review of its mechanisms of neurotoxicity

Przedborski, S., & Vila, M. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(01)00019-6 · Cited by 191

Conditional Expression of Parkinson's Disease-Related Mutant -Synuclein in the Midbrain Dopaminergic Neurons Causes Progressive Neurodegeneration and Degradation of Transcription Factor Nuclear Receptor Related 1

Lin, X. Z., Parisiadou, L., Sgobio, C., Liu, G., Yu, J. H., Sun, L., Shim, H., Gu, X., Luo, J., Long, C., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1731-12.2012 · Cited by 192

shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model

Zharikov, A., Cannon, J. R., Tapias, V., Bai, Q., Horowitz, M. P., Shah, V., Ayadi, A. E., Hastings, T. G., Greenamyre, J. T., & Burton, E. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci64502 · Cited by 190

The concept of alpha-synuclein as a prion-like protein: ten years after

Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183

Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect

Levine, M. S., Cepeda, C., Hickey, M. A., Fleming, S. M., & Chesselet, M. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.08.008 · Cited by 185

Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice

Gómez‐Isla, T., Irizarry, M. C., Mariash, A., Cheung, B. S., Soto, O., Schrump, S. E., Sondel, J., Kotilinek, L., Day, J., Schwarzschild, M. A., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00091-x · Cited by 181

Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies

Bézard, E., Yue, Z., Kirik, D., & Spillantini, M. G. (2012) · Movement Disorders · doi:10.1002/mds.25108 · Cited by 193

Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein

Béraud, D., Hathaway, H. A., Trecki, J., Chasovskikh, S., Johnson, D. A., Johnson, J. A., Federoff, H. J., Shimoji, M., Mhyre, T. R., & Maguire‐Zeiss, K. A. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9401-0 · Cited by 179

Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease

Nuber, S., Petrasch‐Parwez, E., Winner, B., Winkler, J., von Hörsten, S., Schmidt, T., Boy, J., Kuhn, M., Nguyen, H. P., Teismann, P., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3040-07.2008 · Cited by 175

Risk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice

Thiruchelvam, M. J., Powers, J. M., Cory‐Slechta, D. A., & Richfield, E. K. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03139.x · Cited by 174

Valproic Acid is Neuroprotective in the Rotenone Rat Model of Parkinson’s Disease: Involvement of α-Synuclein

Monti, B., Gatta, V., Piretti, F., Raffaelli, S. S., Virgili, M., & Contestabile, A. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9090-5 · Cited by 174

α-Synuclein Negatively Regulates Protein Kinase Cδ Expression to Suppress Apoptosis in Dopaminergic Neurons by Reducing p300 Histone Acetyltransferase Activity

Jin, H., Kanthasamy, A., Ghosh, A., Yang, Y., Anantharam, V., & Kanthasamy, A. G. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5634-10.2011 · Cited by 164

Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies

Peng, C., Gathagan, R. J., & Lee, V. M. ‐. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.018 · Cited by 173

Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice

Wakamatsu, M., Ishii, A., Iwata, S., Sakagami, J., Ukai, Y., Ono, M., Kambe, D., Muramatsu, S., Kobayashi, K., Iwatsubo, T., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.017 · Cited by 157

A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats

Nuber, S., Harmuth, F., Kohl, Z., Adame, A., Trejo, M., Schönig, K., Zimmermann, F., Bauer, C. C., Casadei, N., Giel, C., et al. (2013) · Brain · doi:10.1093/brain/aws358 · Cited by 161

Metabolic Activity Determines Efficacy of Macroautophagic Clearance of Pathological Oligomeric α-Synuclein

Yu, W. H., Dorado, B., Figueroa, H. Y., Wang, L., Planel, E., Cookson, M. R., Clark, L. N., & Duff, K. E. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080928 · Cited by 155

Human Wild-Type α-Synuclein Impairs Neurogenesis

Winner, B., Lie, D. C., Rockenstein, E. M., Aigner, R., Aigner, L., Masliah, E., Kuhn, H. G., & Winkler, J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.11.1155 · Cited by 156

Cytosolic Catechols Inhibit α-Synuclein Aggregation and Facilitate the Formation of Intracellular Soluble Oligomeric Intermediates

Mazzulli, J. R., Mishizen-Eberz, A. J., Giasson, B. I., Lynch, D. R., THOMAS, S. A., Nakashima, A., Nagatsu, T., Ota, A., & Ischiropoulos, H. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0896-06.2006 · Cited by 152

Co‐ordinate transcriptional regulation of dopamine synthesis genes by α‐synuclein in human neuroblastoma cell lines

Baptista, M. J., O’Farrell, C., Daya, S., Ahmad, R., Miller, D. W., Hardy, J., Farrer, M. J., & Cookson, M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01742.x · Cited by 154

Genetic mouse models of Parkinson’s disease

Magen, I., & Chesselet, M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84004-x · Cited by 140

Homozygous alpha-synuclein p.A53V in familial Parkinson's disease

Yoshino, H., Hirano, M., Stoessl, A. J., Imamichi, Y., Ikeda, A., Li, Y., Funayama, M., Yamada, I., Nakamura, Y., Sossi, V., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.022 · Cited by 139

Genetics of parkinsonism

Gwinn, K. A. (2002) · Movement Disorders · doi:10.1002/mds.10173 · Cited by 139

The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy

John, J. S. (2007) · Frontiers in bioscience · doi:10.2741/2714 · Cited by 135

E46K Human α-Synuclein Transgenic Mice Develop Lewy-like and Tau Pathology Associated with Age-dependent, Detrimental Motor Impairment

Emmer, K. L., Waxman, E. A., Covy, J. P., & Giasson, B. I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.247965 · Cited by 138

Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation

Elabi, O. F., Gaceb, A., Carlsson, R., Padel, T., Soylu-Kucharz, R., Cortijo, I., Li, W., Li, J., & Paul, G. (2021) · Scientific Reports · doi:10.1038/s41598-020-80889-8 · Cited by 131

Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases

Breydo, L., & Uversky, V. N. (2011) · Metallomics · doi:10.1039/c1mt00106j · Cited by 129

α-Synucleinopathy models and human neuropathology: similarities and differences

Kahle, P. J. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0302-x · Cited by 132

α-Synuclein Targets the Plasma Membrane via the Secretory Pathway and Induces Toxicity in Yeast

Dixon, C., Mathias, N., Zweig, R. M., Davis, D. A., & Gross, D. S. (2005) · Genetics · doi:10.1534/genetics.104.035493 · Cited by 126

The mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice

Martin, L. J., Semenkow, S., Hanaford, A. R., & Wong, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.008 · Cited by 126

Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1

Dong, Z., Ferger, B., Paterna, J., Vogel, D., Furler, S., Osinde, M., Feldon, J., & Büeler, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2132992100 · Cited by 123

Chapter 6 Molecular and Cellular Biology of Synucleins

Surguchov, A. P. (2008) · International review of cytology · doi:10.1016/s1937-6448(08)01406-8 · Cited by 123

Physiological and pathological properties of α-synuclein

Tofaris, G. K., & Spillantini, M. G. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7217-5 · Cited by 117

Neuropathology and Neurodegeneration in Rodent Brain Induced by Lentiviral Vectormediated Overexpression of α‐Synuclein

Lauwers, E., Debyser, Z., Dorpe, J. V., Strooper, B. D., Nuttin, B., & Baekelandt, V. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00035.x · Cited by 123

Serine 129 Phosphorylation Reduces the Ability of α-Synuclein to Regulate Tyrosine Hydroxylase and Protein Phosphatase 2A in Vitro and in Vivo

Lou, H., Montoya, S. E., Alerte, T. N. M., Wang, J., Wu, J., Peng, X., Hong, C.-S., Friedrich, E. E., Mader, S. A., Pedersen, C. J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100867 · Cited by 115

Parkinson’s disease: experimental models and reality

Jiang, P., & Dickson, D. W. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1788-5 · Cited by 116

Co‐expression of C‐terminal truncated alpha‐synuclein enhances full‐length alpha‐synuclein‐induced pathology

Ulusoy, A., Febbraro, F., Jensen, P. H., Kirik, D., & Romero‐Ramos, M. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07284.x · Cited by 111

Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors

Kirik, D., & Björklund, A. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00164-4 · Cited by 108

Functional models of Parkinson's disease: A valuable tool in the development of novel therapies

Jenner, P. G. (2009) · Annals of Neurology · doi:10.1002/ana.21489 · Cited by 109

Neurobiology of α-Synuclein

Vekrellis, K., Rideout, H. J., & Stefanis, L. (2004) · Molecular Neurobiology · doi:10.1385/mn:30:1:001 · Cited by 108

Metalloproteomics and metal toxicology of α-synuclein

Santner, A. A., & Uversky, V. N. (2010) · Metallomics · doi:10.1039/b926659c · Cited by 104

The usual suspects, dopamine and alpha‐synuclein, conspire to cause neurodegeneration

Mor, D. E., Daniels, M. J., & Ischiropoulos, H. (2019) · Movement Disorders · doi:10.1002/mds.27607 · Cited by 107

Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils

Patterson, J. R., Duffy, M. F., Kemp, C. J., Howe, J. W., Collier, T. J., Stoll, A. C., Miller, K. M., Patel, P., Levine, N. D., Moore, D. J., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104525 · Cited by 108

Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice

Tanji, K., Mori, F., Mimura, J., Itoh, K., Kakita, A., Takahashi, H., & Wakabayashi, K. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0676-z · Cited by 102

Peroxidase Mechanism of Lipid-dependent Cross-linking of Synuclein with Cytochrome c

Bayır, H., Kapralov, A. A., Jiang, J., Huang, Z., Tyurina, Y. Y., Tyurin, V. A., Zhao, Q., Belikova, N. A., Vlasova, I. I., Maeda, A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900418200 · Cited by 102

Increased sensitivity to MPTP in human α-synuclein A30P transgenic mice

Nieto, M., Gil-Bea, F. J., Dalfó, E., Cuadrado‐Tejedor, M., Cabodevilla, F., Sánchez, B., Catena, S., Sesma, T., Ribé, E. M., Ferrer, I., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.010 · Cited by 100

Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human α-synuclein

Yavich, L., Oksman, M., Tanila, H., Kerokoski, P., Hiltunen, M. O., van Groen, T., Puoliväli, J. T., Männistö, P. T., Garcia-Horsman, A., MacDonald, E., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.010 · Cited by 103

Etiology of Parkinson's disease: Genetics and environment revisited

Steece‐Collier, K., Lad, E. M., & Kordower, J. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242594999 · Cited by 99

Alterations in corticostriatal synaptic plasticity in mice overexpressing human α-synuclein

Watson, J. B., Hatami, A., David, H., Masliah, E., Roberts, K., Evans, C., & Levine, M. S. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.01.021 · Cited by 103

Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons

Daher, J. P. L., Ying, M., Banerjee, R., McDonald, R. S., Hahn, M. D., Yang, L., Beal, M. F., Thomas, B., Dawson, V. L., Dawson, T. M., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-34 · Cited by 95

Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice

Gómez‐Isla, T., Irizarry, M. C., Mariash, A., Cheung, B. S., Soto, O., Schrump, S. E., Sondel, J., Kotilinek, L., Day, J., Schwarzschild, M. A., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00091-x · Cited by 181

Conditional control of human wild-type and Parkinson's disease-associated mutant alpha-synuclein in transgenic mouse brain

Nuber, S., Schmidt, T., Berg, D., Neumann, M., Holzmann, C., Fendt, M., Grasshoff, U., Schmitt, I., Bornemann, A., Zimmermann, F., et al. (2004) · Aktuelle Neurologie · doi:10.1055/s-2004-833272

Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters

Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., & Masliah, E. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10231 · Cited by 502

Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons

Daher, J. P. L., Ying, M., Banerjee, R., McDonald, R. S., Hahn, M. D., Yang, L., Beal, M. F., Thomas, B., Dawson, V. L., Dawson, T. M., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-34 · Cited by 95

Dopaminergic neuron loss and up‐regulation of chaperone protein mRNA induced by targeted over‐expression of alpha‐synuclein in mouse substantia nigra

Martin, J. L. S., Klucken, J., Outeiro, T. F., Nguyen, P. T., Keller-McGandy, C. E., Cantuti‐Castelvetri, I., Grammatopoulos, T. N., Standaert, D. G., Hyman, B. T., & McLean, P. J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04310.x · Cited by 184